In our previous series of studies, we found that Srx preferentially interacts with Prx4 due to its intrinsically higher binding affinity, and the Srx–Prx4 axis contributes to the activation of oncogenic signaling pathways in different types of human cancer [9,11,12]. This evidence concerns the gene SRXN1 and cancer.